Worsening Heart Failure clinical trials

Explore recruiting worsening heart failure clinical trials.

Recruiting worsening heart failure studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Worsening Heart Failure trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

Corticotrophin Releasing Factor 2 Agonist For the Treatment of Worsening Heart Failure (WHF) – The CRAFT-WHF Study

Czechia, Spain, Romania, Hungary, Poland

Therapeutic exploratory (Phase II) EU CTIS Study details

A Multicenter, Randomized, Double-Blind, Parallel Group, Placebo-Controlled Trial to Evaluate the Effect of In-Hospital Initiation of Dapagliflozin on Clinical Outcomes in Patients Who Have Been Stabilized During Hospitalization for Acute Heart Failure

Poland, Hungary, Czechia

Phase III and phase IV (Integrated) EU CTIS Study details

A phase III, randomized, open-label, blinded endpoint, comparative trial of ferric derisomaltose versus no intravenous iron in iron-deficient subjects with symptomatic chronic heart failure

Poland, Lithuania, Croatia, Hungary, Slovakia, Latvia +6 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

Cluster and Registry trial Of the Working group of heart failure in Denmark. Are CarvedilOl and Metoprolol succinate comPArable treatments in heart failure patients with Reduced Ejection fraction.

Denmark

Therapeutic use (Phase IV) EU CTIS Study details

Hydralazine-ISDN in Patients With Chronic Heart Failure - Hydralazine Heart Failure Trial (H-HeFT) Metformin in Patients with Chronic Heart Failure and Diabetes or Insulin Resistance - Metformin Heart Failure Trial (Met-HeFT) A randomized, 2 x 2 factorial designed, double-blind, placebo controlled study (DANHEART).

Denmark

Therapeutic confirmatory (Phase III) EU CTIS Study details

Initiation of angiotensin receptor-neprilysin inhibitor (ARNi) and sodium-glucose cotransporter-2 inhibitors (SGLT2i) in patients with heart failure with reduced ejection fraction (HFrEF): the INITIATE-HFrEF randomized open-label trial

Portugal

Phase III and phase IV (Integrated) EU CTIS Study details

Worsening Heart Failure trials by city

Worsening Heart Failure in Toronto Worsening Heart Failure in Vancouver Worsening Heart Failure in Montreal Worsening Heart Failure in Calgary Worsening Heart Failure in Edmonton Worsening Heart Failure in Ottawa Worsening Heart Failure in Winnipeg Worsening Heart Failure in Quebec City Worsening Heart Failure in Hamilton Worsening Heart Failure in Kitchener Worsening Heart Failure in London Worsening Heart Failure in Halifax Worsening Heart Failure in New York Worsening Heart Failure in Los Angeles Worsening Heart Failure in Chicago Worsening Heart Failure in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease